Literature DB >> 28029428

The serotonin transporter gene 5-HTTLPR polymorphism is associated with affective psychoses but not with schizophrenia: A large-scale study in the Russian population.

Vera Golimbet1, Galina Korovaitseva1, Tatyana Lezheiko1, L I Abramova1, V G Kaleda1.   

Abstract

BACKGROUND: Affective syndrome is thought to be a key feature that differentiates schizophrenia from schizoaffective disorder (SA) and bipolar disorder with psychotic features (BDP). However genetic underpinnings of these differences remain unresolved.
OBJECTIVES: We compared clinical variables of affective psychoses (SA, BDP and schizophrenia with affective symptoms (AFF SCZ)) and schizophrenia without affective symptoms (non-AFF SCZ) and searched for a genetic variant that may differentiate affective psychosis from non-AFF SCZ.
METHODS: A total of 2677 subjects, including 831 patients with affective psychosis, 785 patients with non-AFF SCZ and 1061 healthy controls, were used. Clinical symptoms were assessed with the PANSS. The sample was genotyped for 5-HTTLPR polymorphism of the serotonin transporter gene.
RESULTS: The diagnostic groups differed significantly on demographic and clinical variables. The percentage of men was higher, the current age and age at illness onset were lower in non-AFF SCZ and SA compared to AFF SCZ and BDP. The severity of positive and negative symptoms decreased significantly from group to group in the following manner: non-AFF SCZ>AFF SCZ>SA>BDP. There was the association between 5-HTTLPR polymorphism and affective psychosis (p=0.01). The frequency of the SS genotype was higher in the affective psychosis group compared to non-AFF SCZ and controls. No differences in the genotype distribution were identified between the non-AFF SCZ group and controls. LIMITATIONS: Difficulties in the differentiation between non-AFF SCZ and AFF SCZ or SA and between AFF SCZ and SA due to uncertain diagnostic boundaries between these conditions.
CONCLUSIONS: SA is intermediate between non-AFF SCZ and BDP in the severity of positive and negative symptoms. The first episode patients, carriers of the SS genotype have a higher risk of developing affective psychosis than non-AFF SCZ. This finding carries implications for the prognosis of psychosis outcomes in the first-episode patients.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Affective syndrome serotonin transporter gene; Bipolar disorder; Outcome; Schizoaffective disorder; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 28029428     DOI: 10.1016/j.jad.2016.10.020

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  4 in total

1.  Effects of a GWAS-Supported Schizophrenia Variant in the DRD2 Locus on Disease Risk, Anhedonia, and Prefrontal Cortical Thickness.

Authors:  Margarita V Alfimova; Nikolay V Kondratyev; Alexander S Tomyshev; Irina S Lebedeva; Tatyana V Lezheiko; Vasiliy G Kaleda; Lilia I Abramova; Vera E Golimbet
Journal:  J Mol Neurosci       Date:  2019-05-03       Impact factor: 3.444

2.  Serotonin transporter functional polymorphisms potentially increase risk of schizophrenia separately and as a haplotype.

Authors:  Rana Ghamari; Fatemeh Yazarlou; Zahra Khosravizadeh; Atefeh Moradkhani; Elaheh Abdollahi; Fatemeh Alizadeh
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

3.  Association between the SLC6A4 gene and schizophrenia: an updated meta-analysis.

Authors:  Feng-Ling Xu; Bao-Jie Wang; Jun Yao
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-28       Impact factor: 2.570

4.  Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium.

Authors:  Thomas G Schulze; Аleksandr О Kibitov; Olga Yu Fedorenko; Vera E Golimbet; Svetlana А Ivanova; Аnastasia Levchenko; Raul R Gainetdinov; Arkady V Semke; German G Simutkin; Аnna E Gareeva; Аndrey S Glotov; Anna Gryaznova; Ivan Y Iourov; Evgeny M Krupitsky; Igor N Lebedev; Galina E Mazo; Vasily G Kaleda; Lilia I Abramova; Igor V Oleichik; Yulia A Nasykhova; Regina F Nasyrova; Anton E Nikolishin; Evgeny D Kasyanov; Grigory V Rukavishnikov; Ilgiz F Timerbulatov; Vadim M Brodyansky; Svetlana G Vorsanova; Yury B Yurov; Tatyana V Zhilyaeva; Anzhelika V Sergeeva; Elena A Blokhina; Edwin E Zvartau; Anna S Blagonravova; Lyubomir I Aftanas; Nikolay А Bokhan; Zurab I Kekelidze; Tatyana V Klimenko; Irina P Anokhina; Elza K Khusnutdinova; Tatyana P Klyushnik; Nikolay G Neznanov; Vadim A Stepanov
Journal:  Mol Psychiatry       Date:  2019-01-21       Impact factor: 15.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.